SCHEMBL4356541

SCHEMBL4356541

NC(=O)CC[C@H](NC1CC1)C(=O)OC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
MMP2 P08253 2/20 0.44
MMP9 P14780 2/20 0.44
SMYD3 Q9H7B4 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SLC1A5 Q15758 1/20 0.42
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
SCN1A P35498 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPY1R P25929 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364695 0.94 KDM4E (0.45) KDM4EMMP2MMP9SMYD3KMT2A
SCHEMBL5651929 0.90 PRMT5 (0.46) KDM4EMMP2MMP9SMYD3SMN1; SMN2
SCHEMBL5652199 0.83 KDM4E (0.45) KDM4EMMP2MMP9SMN1; SMN2KMT2A
SCHEMBL5651555 0.82 KDM4E (0.51) KDM4EMMP2MMP9SMN1; SMN2KMT2A
SCHEMBL2247315 0.77 KDM4E (0.46) KDM4EMMP2MMP9SMN1; SMN2NPC1
SCHEMBL4357430 0.77 KDM4E (0.46) KDM4EMMP2MMP9SMN1; SMN2NPC1
SCHEMBL4365446 0.77 KDM4E (0.46) KDM4EMMP2MMP9SMN1; SMN2KMT2A
SCHEMBL4621031 0.77 KDM4E (0.46) KDM4EMMP2MMP9SMN1; SMN2NPC1
SCHEMBL4369490 0.76 KDM4E (0.44) KDM4EMMP2MMP9SMN1; SMN2KMT2A
SCHEMBL5651549 0.76 KDM4E (0.44) KDM4EMMP2MMP9NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 KDM4E 1232/4885MMP2 49/4885MMP9 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.